Biomarker levels and clinical response
PsA
Participants in the guselkumab group, but not the placebo group, who achieved an ACR20 response at Week 24 exhibited higher baseline IL-22 and IFNγ levels compared with ACR20 nonresponders (Fig. Baseline serum cytokine levels and clinical response at Week 24 in participants with TNFi-IR PsA from COSMOS by ACR20 response or IGA 0/1 response and change from baseline in serum IL-6 level by ACR20 or IGA 0/1 response over time. (Participants in the guselkumab group who achieved an ACR20 response at Week 24 exhibited a significantly greater reduction in IL-6 level from baseline at Week 4 compared with ACR20 nonresponders (Fig. 